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Abstract 
 
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using 
CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex virus type-1 
thymidine kinase (HSV1-TK) and interleukin (IL)-13 zetakine chimeric antigen receptor (CAR), 
is a treatment strategy with considerable potential. To optimize this and related immunotherapies, 
it may be helpful to monitor CTL viability and trafficking to glioma cells. We show that 
noninvasive positron emission tomography (PET) imaging with 9-[4-[18F]fluoro-3-
(hydroxymethyl)butyl]guanine ([18F]FHBG) can track HSV1-tk reporter gene expression present 
in CAR-engineered CTLs. [18F]FHBG imaging was safe and enabled the longitudinal imaging of 
T cells stably transfected with a PET reporter gene in patients. Further optimization of this 
imaging approach for monitoring in vivo cell trafficking should greatly benefit various cell-based 
therapies for cancer. 
  
 4 
Introduction 
  
Immunotherapy holds great potential for the treatment and management of cancer patients with 
advanced disease (1). Through numerous divergent mechanisms, including monocyte maturation 
in the presence of tumor antigens (2) and the genetic engineering of immune cells (3), the body’s 
adaptive immune system can be primed to target malignancies normally recognized as ‘self’. 
Although the success of recent Phase III trials has validated the principle that immunotherapy 
can sometimes extend cancer patient survival (4), tumor cells can escape immune surveillance 
and develop resistance to immunotherapy (5). Examples of resistance mechanisms include the 
regulation of immune checkpoints (6), resistance to cell-death signaling (7), or regulation by 
other tumor-associated immune cells, such as regulatory T cell lymphocytes (8). Given the 
variable success of immunotherapy in the clinic (9-11), there is an urgent need to design 
noninvasive techniques that could give early indications of response to treatment and help 
predict patient outcome.  
 
Current methods used for the assessment of tumor response to therapy primarily rely on 
measurements of tumor size through anatomical imaging using the response evaluation criteria in 
solid tumors (RECIST) (12). The limitations of anatomical imaging for response monitoring in 
solid tumors have been well documented (13). Assessment of immunotherapy efficacy provides 
particular challenges in that the influx of effector cells to the tumor microenvironment may result 
in “pseudoprogression” as defined by RECIST, which is not linked to long-term outcome (14). 
These limitations have led to the development of a specific set of immune-related response 
criteria (irRC) (14, 15). irRC measurements, however, provide no biological information and can 
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take between 8–12 weeks for an initial response assessment, by which time non-responding 
patients may have missed their therapeutic window and experienced unnecessary therapy-related 
toxicity. In addition, adaptive immune responses involving T and B lymphocytes, which have 
demonstrated great therapeutic potential, require monitoring of immune cell trafficking to the 
tumor site, lymphocyte retention, and immune cell engagement with the tumor cells. At present, 
techniques to non-invasively assess the in vivo viability and trafficking of these immune cells in 
cancer patients are not available. 
 
We previously provided a demonstration of imaging cells in a single case report using reporter 
gene technology (16). In that case study, therapeutic T cells expressing a positron emission 
tomography (PET) reporter gene were injected into the tumor resection site of a 57-year old male 
high-grade glioma patient and then visualized by molecular imaging with a PET reporter probe 
(16). For that study, we used genetically modified CD8+ autologous cytotoxic T lymphocytes 
(CTLs) stably expressing the chimeric antigen receptor (CAR) interleukin (IL)-13 zetakine for 
IL13Rα2+ tumor targeting (17-19) and the herpes simplex virus type-1 thymidine kinase gene 
(HSV1-tk) as a dual-purpose suicide (20, 21) and imaging reporter gene (Fig. 1) (22, 23). HSV1-
tk was fused in-frame with the hygromycin phosphotransferase (hph) gene and expressed as a 
fusion protein. HPH expression conferred hygromycin B resistance for dominant positive 
selection. Through imaging of HSV1-tk reporter gene expression using 9-[4-[18F]fluoro-3-
(hydroxymethyl)butyl]guanine ([18F]FHBG), which is a fluorine-18 radiolabeled analogue of the 
anti-herpes drug penciclovir (Fig. 1 insert), we were able to image [18F]FHBG trapping in the 
brain tumor, thought to correspond to CTL accumulation. This corroborated the extensive 
preclinical assessment of this targeted strategy (24). This study in a single patient was limited, 
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however, because at that time we only had FDA approval to perform one PET scan after the 
infusion of CTLs and did not have a critical baseline PET image before CTL injection. We were 
therefore unable to confirm that the brain-associated [18F]FHBG signal was CTL-specific (22). 
 
Expanding on this pilot case study, we sought to assess the ability of [18F]FHBG to 
longitudinally monitor CTL trafficking, survival, and proliferation in multiple patients with 
recurrent high-grade gliomas that were resistant to conventional therapies. Under this protocol, 
seven patients received several infusions of either autologous or allogeneic engineered CTLs 
(Fig. 1). CTL location and response were noninvasively measured by PET using a strategy 
outlined in Fig. 2. In addition, we evaluated the safety of the CTLs injected into the central 
nervous system and the safety of recombinant human IL-2 delivery in conjunction with CTL 
adoptive cell transfer, a strategy used to prolong the survival of engineered CTLs and potentially 
improve their therapeutic efficacy. 
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Results 
Patient enrolment and CTL characterization 
To conduct a detailed evaluation of the utility of [18F]FHBG to track genetically engineered 
CTLs for immunotherapy, we enrolled a total of 4 men and 3 women (average age of 57 ± 8 
years old with recurrent high-grade glioma, under two separate IRB-approved protocols (Table 
1). Patient 1 in this study is the patient from our previous case report (16). Autologous 
(NCT00730613)(17) and allogeneic (NCT01082926) CTLs for immunotherapy were engineered 
to express the tumor-targeting IL-13 zetakine CAR and the wild-type HSV1-tk gene reporter. 
This CAR recognizes IL13R2, a cell surface receptor expressed in over 50% of glioblastoma 
cells, but not in normal brain tissue (25, 26). The CTLs were > 99% CD8. We first confirmed our 
previous finding (27, 28) that [18F]FHBG specifically accumulates in genetically modified CTLs 
expressing the HSV1-tk reporter gene rather than the naïve parental cells obtained from a human 
buffy coat (fig. S1). Here, [18F]FHBG accumulation at one hour was 12-fold higher in 
transfected CTLs versus non-transfected parental cells, at 7.37 ± 2.17 % [18F]FHBG uptake/108 
cells and 0.61 ± 0.27 % [18F]FHBG uptake/108 cells, respectively (n = 3; P = 0.006). 
Furthermore, 60 min incubation with [18F]FHBG had no significant effect on cell proliferation of 
non-transduced CTLs or those expressing HSV1-tk (taken from Patient 1), up to 48 h after 
addition of the radiotracer (fig. S2; P > 0.05). 
 
Safety 
[18F]FHBG PET scans were performed in patients before and after CTL infusions to assess the 
spatial location of the engineered CTLs within the body. Patients 3-7 received IL-2 infusions to 
improve CTL survival. Patient vital signs and lab results were within normal limits throughout 
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and after [18F]FHBG administration. Patient 1 experienced a mild, transient headache without 
any neurological deficits. Patient 2 developed new neurological deficits two days before the 
initiation of CTL therapy, corresponding to vasogenic cerebral edema (diagnosed from MRI) and 
not related to either [18F]FHBG or disease progression. Patient 5 had a mild rash on the shoulders 
with redness on the lower face at two hours after intravenous injection of [18F]FHBG during pre-
CTL imaging. Twenty-five milligrams of oral diphenhydramine was subsequently administered 
to Patient 5, and the rash resolved within one hour. None of the seven patients had any major or 
life-threatening events related to [18F]FHBG or CTL injections throughout the duration of their 
participation within this trial. Most patients died within 12 months after the last CTL infusion. 
Patient survival data after initial diagnosis and since the first CTL infusion are presented in table 
S1.  
 
Biodistribution 
The stability and detailed pharmacokinetics of [18F]FHBG in healthy volunteers have been 
previously reported (29). Here, we observed similar radiotracer biodistribution (fig. S3), as 
assessed by standardized uptake value (SUV)mean measurements on the pre- and post-CTL 
injection scans using a 50 mm diameter spherical volume of interest. In pre-CTL treatment scans, 
at a mean time of 137 ± 11 min after injection of [18F]FHBG (n = 6), the average (±SD) SUVmean 
was 0.25 ± 0.08 for left ventricular blood pool, 1.57 ± 0.69 for right hepatic dome, 0.09 ± 0.04 
for lung parenchyma, and 0.36 ± 0.14 for right thigh. There was no significant difference in 
[18F]FHBG uptake in these tissues after immunotherapy (P > 0.05; table S2). In the normal brain, 
contralateral to either suspected lesions or resection sites, and before CTL infusions, [18F]FHBG 
SUVmean was 0.04 ± 0.01 (n = 6). After CTL infusions, we observed no significant change in 
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normal brain uptake (SUVmean = 0.04 ± 0.01; n = 6; P > 0.05). We next quantified the amount of 
[18F]FHBG activity in the vicinity of tumors where a breakdown of the blood-brain barrier was 
observed based on the post-contrast T1-weighted MRI scan. The low background from non-
target tissue (normal brain) permitted visualization of brain tissue abnormalities such as tumors 
(Fig. 3A), with [18F]FHBG uptake in untreated tumors and sites of tumor resection statistically 
higher than in the normal contralateral brain tissue (3.3-11.5-fold increase, P = 0.0009).  
 
[18F]FHBG imaging of CTLs in patients 
Given the observation of some nonspecific [18F]FHBG retention in both gliomas and previous 
surgical sites before CTL infusion, it was essential to perform baseline and follow-up scans in 
the same patients after CTL injection (16). A total of ten tumor foci were analyzed in the seven 
patients, with two sites each assessed for Patients 1, 4, and 7. We did not obtain a pre-CTL 
[18F]FHBG scan in Patient 1 because the use of two [18F]FHBG scans per patient was not yet 
approved by the FDA when the patient was enrolled in 2006. Qualitative assessment of 
[18F]FHBG uptake by PET imaging revealed an increase in PET signal after CTL infusions, 
likely corresponding with CTL cell trafficking and viability (Fig. 3A & B and movie S1).  
 
To quantify [18F]FHBG radioactivity and distribution, we initially evaluated the maximum 
concentration (SUVmax) of [
18F]FHBG on pre- and post-CTL injection scans, where we observed 
a large variation in response, ranging from +53% (Patient 2) to -15% (Patient 7, lesion B) (fig. 
S4). After intracerebral injection, there is potential for CTLs to diffuse in the surgical cavity or 
the brain parenchyma. To optimize the monitoring of CTL trafficking to targeted areas, better 
imaging metrics were needed to replace single-voxel measurements such as SUVmax, particularly 
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when the localization of CTLs, and therefore the volume of interest (VOI), was unknown. The 
first challenge was to define an accurate VOI. Given the availability of contrast-enhanced MR 
images taken from the same patients before and after CTL infusions, it was possible to derive 
VOIs from enhancing regions of the tumor. MRI-based [18F]FHBG voxel analysis, however, 
excluded radioactivity outside of enhancing regions (fig. S5A), which may represent CTLs that 
have failed to target to the tumor or potential targeting to tumor cells that were not visible on 
MRI. Analysis of these therapeutic cells is essential, because an indication of poor CTL 
trafficking to tumor tissue has implications for the efficacy of the immunotherapy strategy. To 
circumvent the exclusion of non-tumor-associated radioactivity, we used different SUVmax 
thresholds to draw a growing volume of interest. The contouring algorithm used selected the 
highest [18F]FHBG SUV as the center of the VOI before generating peripheral limits based upon 
the desired threshold value, as illustrated in fig. S5B. VOIs for all patients were analyzed using 
threshold values from 10% to 90% in 10% increments (fig. S6). For [18F]FHBG analysis, a 50% 
SUVmax threshold was selected to create VOIs that best represented [
18F]FHBG distribution 
throughout the brain.  
 
Having determined a suitable, non-biased method for VOI delineation, the next challenge was to 
devise a method of analysis that could assess CTL trafficking 1) to a region within the brain of 
fixed volume, such as a tumor and 2) when the [18F]FHBG signal was widely dispersed after 
CTL infusions, for example as a result of poor trafficking to the tumor site, CTL dilution in the 
ventricular system, or correct trafficking to tumor tissue not visible by MRI. The SUVmean 
provided a means to assess tumor-specific CTL trafficking when the VOI did not change 
between pre- and post-CTL scans (fig. S7; Patients 2 and 6), but failed to accurately depict 
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changes in [18F]FHBG radioactivity after CTL infusions in patients for whom the VOI was 
increased in the post-CTL scan. To detect potential changes in [18F]FHBG radioactivity before 
and after CTL infusions, regardless of the size of the VOI, we next assessed the total [18F]FHBG 
activity (SUVmean  volume of interest) for each scan.  
 
Analysis of the total activity in patients for whom the size of the VOI did not change, such as 
Patient 6, clearly indicated a shift in SUV histograms after CTL infusions (Fig. 3C), 
corresponding to a doubling of total [18F]FHBG activity from 4.1 to 8.4 in this patient. A further 
example is provided with Patient 2, whose total activity was increased from 10.1 to 20.3 (fig. S8). 
Total activity measurements were also able to detect radioactivity disseminated over an increased 
volume after CTL infusions, an example of which is illustrated in Fig. 4A,B (Patient 7). Here, as 
evident from histogram analysis (Fig. 4C), despite an absence of a large change in median 
[18F]FHBG radioactivity between scans, the total radioactivity increased 3.7-fold, from 1.8 in the 
pre-CTL scan to 6.8 post-CTL infusions, in part because of a substantial increase in the VOI. A 
further example of changes in [18F]FHBG total activity after CTL infusions in the absence of a 
change in SUVmean was observed with Patient 3 (fig. S9). Across all patients, in clinically-
confirmed sites of tumor recurrence, [18F]FHBG total activity was significantly increased in the 
PET scan after CTL infusions versus the baseline scan (Fig. 5; P = 0.014; paired Wilcoxon test). 
 
[18F]FHBG uptake in untreated tumor sites  
In patients with multifocal disease, in addition to the injected tumor site, distant tumor foci not 
injected with CTLs were also analyzed with [18F]FHBG (Patient 7; Fig. 4D-F). No CTLs were 
infused locally, and therefore no changes in [18F]FHBG uptake at the site were expected between 
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scans. In the post-CTL scan, however, a 66% increase in total [18F]FHBG activity was measured 
by comparison to the baseline scan, from 1.6 to 2.7, further supported by minimal changes in the 
dispersion of voxel intensities (Fig. 4F). This is in contrast to the 5-15-fold changes observed at 
the injected disease site (Fig. 5). Small changes in [18F]FHBG uptake at untreated tumor sites 
after CTL versus baseline scans were confirmed in an additional patient (Patient 4). In this 
patient, [18F]FHBG total activity in the CTL-treated focus was increased 2.2-fold on the post-
CTL scan, increasing from 2.9 at baseline to 6.3 at the site of tumor recurrence, whereas the 
focus corresponding to the primary untreated site increased just 32%, from 2.4 to 3.2 (fig. S10).  
The modest increase in [18F]FHBG activity in the untreated sites in these two patients may 
represent trafficking of CTLs to distant tumor foci in the brain.  
 
Challenges of CTL tracking with [18F]FHBG 
As a result of the complexity of implementing a robust immunotherapy treatment strategy for the 
treatment of high-grade gliomas in humans, a number of key experimental limitations presented 
themselves during the course of this study. In Patient 1, FDA restrictions prevented the 
acquisition of a pre-CTL [18F]FHBG scan, however, we have previously shown in a post-CTL 
[18F]FHBG scan that CTL-associated radioactivity exquisitely corresponded to enhancing foci on 
MRI, not detectable by [18F]FDG-PET (fig. S11) (16). Therefore, we believed that CTLs had 
likely properly migrated to the target tumor areas, but given that high-grade glioma cells in pre-
CTL scans were [18F]FHBG-positive in other patients, we were unable to confirm this hypothesis.  
 
The CTL infusion techniques used in this study are also expected to play a role in the survival of 
CTLs in vivo and their homing to the tumor site. In Patient 3 (NCT01082926), the CTLs were 
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injected using a slow infusion technique over several hours. This delivery technique resulted in 
cell clumping that may have reduced cell viability, however, [18F]FHBG total activity was still 
increased 2.4-fold from 3.5 to 8.4 in this patient (fig. S9), reflecting the likely survival of a 
substantial proportion of these CTLs. The positioning of the Rickham catheter tip next to the 
ventricular system may also affect optimal CTL trafficking to tumor sites. In Patients 4 and 5, the 
Rickham catheter tip was positioned next to the ventricular system. In these patients, CTLs likely 
diffused into the cerebrospinal fluid, as evidenced by the diffusion of [18F]FHBG within the 
lateral ventricles in the post-CTL [18F]FHBG scan, which was not observed on the pre-CTL scan 
(fig. S10A,B). These findings suggest that the dilution phenomenon might potentially affect the 
therapeutic effect by reducing the overall number of CTLs at the recurrent tumor site. On the 
other hand, this might be beneficial for patients whose tumors are located next to the ventricular 
system and are at higher risk of spinal leptomeningeal dissemination (30, 31). Nevertheless, 
these explanations require further validation.  
 
The tumor vascular supply may also affect the ability to track CAR-engineered CTLs with 
[18F]FHBG. In Patient 5, the recurrent glioma was adherent to the dura mater, which contributed 
to a rich vascular supply with disrupted blood-tumor barrier. As a consequence, intravenously 
injected [18F]FHBG could readily diffuse from the leaky vascular supply into the tumor. In this 
patient, baseline [18F]FHBG total activity was substantially higher at 23.1, compared to a mean 
total activity of 6.2 ± 2.9 for all other patients for whom a pre-CTL scan was available (n = 7 
foci). It is highly plausible that elevated baseline [18F]FHBG tumor uptake is a direct result of 
increased delivery and non-specific retention of the radiotracer in the tumor. Furthermore, high 
baseline [18F]FHBG uptake on pre-CTL infusion scans may confound accurate measurement of 
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CTL tracking. Indeed, [18F]FHBG total activity in Patient 5 was increased by just 21% in the 
post-CTL infusion scan when compared to the baseline scan, at 28.1 and 23.1, respectively (fig. 
S12).  
 
 
Discussion 
 
Malignant gliomas are the most frequently occurring primary brain tumors and are associated 
with a very poor survival rate (32). Tremendous efforts have focused on the design of diagnostic 
and therapeutic tools for this devastating disease, among which targeted immunotherapy holds 
great promise (33). Unlike current conventional cancer treatments, the potential of 
immunotherapy resides in selectively targeting cancer cells while leaving healthy cells 
unharmed. One of the main immunotherapeutic methods under exploration is through CAR 
engineering of CTLs to become tumor-reactive and tumor-specific (34).  
 
To fully validate immunotherapeutic strategies, it is crucial to monitor the viability, 
biodistribution, and trafficking of therapeutic cells to the site of the tumor. At present there is no 
means to assess the fate of these cells. Imaging via MRI, optical, or nuclear medicine-based 
techniques, however, has the potential to noninvasively monitor and track these cells in vivo. 
Two main approaches have been undertaken for cell tracking: direct and indirect labeling 
methods (35, 36). Direct labeling of cells involves incubation and retention of an imaging agent 
by the therapeutic cells which are injected into the subject, with the imaging agent monitored 
over a time course of hours to days. One example of a direct labeling method, using 
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superparamagnetic iron oxide (SPIO)-labeled cells, has demonstrated great potential for the 
accurate assessment of image-guided cell injection into the tissue of interest (37).  
 
Although they are relatively inexpensive and easy to perform, direct labeling methods are 
hampered by potential toxicity to the therapeutic cells (38). Moreover, the contrast agent 
becomes diluted upon cell division and is lost from the cells upon cell death, making image 
analysis difficult to interpret (39). To circumvent these issues, we and others have developed 
noninvasive indirect imaging reporter strategies to successfully track these cells (40-43). These 
methods enable imaging over the entire lifetime of the cell, with signal maintained after cell 
division, and provide information regarding cell viability (39). The majority of the signal is 
obtained from living cells because the production of the imaging reporter is dependent on 
translation of a gene into a functional protein, in a process requiring ATP. In this study, we 
demonstrated in humans that therapeutic CAR T cells can be detected noninvasively after 
intracranial adoptive transfer, through the PET imaging of a reporter gene. 
 
Here, CTLs were engineered to express the tumor-targeting IL-13 zetakine CAR and the wild-
type HSV1-tk reporter gene, with HSV1-TK expression monitored by [18F]FHBG PET imaging. 
In cell culture, [18F]FHBG uptake was 12-fold higher in HSV1-tk-expressing CTLs compared to 
naïve human T lymphocytes that were isolated from a human buffy coat. [18F]FHBG incubation 
also had no effect on CTL proliferation rate in cell culture, presumably due to the low amount of 
mass tracer used. The functional and cytolytic activity of CTLs obtained from Patient 1 has been 
shown previously (18). For all other patients, insufficient tumor material was obtained at biopsy 
to enable primary GBM or patient-derived xenografts to be established in immunocompromised 
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mice. We were therefore unable to assess functional activity of the CTLs against each patient’s 
GBM cells. 
 
[18F]FHBG is a relatively poor substrate for mammalian thymidine kinases, resulting in low 
background accumulation in cells not expressing the HSV1-tk reporter gene, such as naïve human 
T lymphocytes and normal brain cells (22). Negligible brain-associated radioactivity was 
observed in [18F]FHBG scans both before and after CTL infusions, with [18F]FHBG not able to 
diffuse across an intact blood-brain barrier (BBB) (29), thereby providing an ideal low 
background signal. In glioma patients with a disrupted BBB, however, [18F]FHBG accumulation 
in tumors was evident before CTL infusions. Retention of [18F]FHBG in untreated tumors before 
CTL infusion may result from slow washout of the radiotracer from the resection cavity or be a 
consequence of off-target retention in the tumor cells. It was therefore vital to perform 
[18F]FHBG imaging both before and after CTL infusions for accurate monitoring of this CAR T 
cell therapy strategy. 
 
Because the location of the CTLs within the brain cavity were unknown, better imaging metrics 
were needed to replace single-voxel measurements such as SUVmax to define both the location 
and quantity of the therapeutic cells. We used a contouring algorithm based upon a set 
radioactivity threshold value relative to SUVmax to determine an accurate VOI. Through this 
method we could accurately assess not only tumor-associated CTLs, but also poorly targeted 
CTLs and CTLs that had targeted diffusely growing tumor cells undetected on contrast-enhanced 
MRI. For quantitation, we assessed [18F]FHBG total activity within the generated ROI (SUVmean 
 volume of interest) as an unbiased measure of [18F]FHBG signal in a fixed volume region 
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within the brain (namely the tumor) and in the setting where the [18F]FHBG signal, and therefore 
CTLs, was widely dispersed after CTL infusions. This metric is comparable to total lesion 
glycolysis used with [18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) PET, which is a more 
sensitive marker than SUVmax or SUVmean for the evaluation of therapeutic response and 
prognosis (44-46). 
 
The noninvasive imaging of genetically engineered CTLs for cancer immunotherapy held some 
specific challenges. Because [18F]FHBG was the first PET reporter probe to receive an 
investigational new drug (IND) approval from the FDA (IND #61,880), strict regulations 
prevented repeat [18F]FHBG scans before and after immunotherapy for the initial patient. This, 
coupled with the complexity of the immunotherapy strategy, markedly high cost (estimated at ~ 
$200,000 USD per patient), and limited access to this patient population restricted the number of 
patients who were enrolled in this study. In spite of these obstacles, a significant increase in 
[18F]FHBG total activity representing CTL trafficking to tumor sites was observed across our 
patient cohort (P = 0.014; paired Wilcoxon test), highlighting the potential of this imaging 
strategy. It is unclear, however, whether IL-2-mediated changes in BBB permeability contributed 
to changes in [18F]FHBG signal in the post-CTL scan. Moreover, we were unable to assess 
accurate delivery of CTLs to the tumor and its effect on differential [18F]FHBG uptake. These 
variables will need to be evaluated in future studies. Although the absolute intrinsic uptake of 
[18F]FHBG per cell remained relatively low, the mutant HSV1-tk reporter gene, HSV1-sr39tk, 
may provide increased sensitivity for detection through increased trapping of [18F]FHBG in 
engineered cells in future clinical trials (23, 47). Finally, because of the limited number of 
patients enrolled on this study, it was not possible to link changes in [18F]FHBG signal before 
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and after CTL infusions to clinical outcome. Future work will need to link CTL trafficking and 
viability, as measured by [18F]FHBG PET, to tumor response and patient survival. In summary, 
this work highlights an approach that uses a specific PET tracer to image HSV1-tk reporter gene 
expression in engineered CTLs to monitor CAR therapy for the treatment of high-grade gliomas. 
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Materials and methods 
Study design 
The primary research objective was to test the feasibility of [18F]FHBG gene reporter imaging 
for the monitoring of therapeutic T cell distribution and viability in glioma patients. Patients 
from 18-70 years old with an average clinical status (a Karnofsky Performance Status > 60) and 
evidence of disease progression twelve weeks after the end of radiotherapy were included in this 
study. Exclusion criteria were a survival expectation of less than four weeks, any organ 
dysfunction, a large tumor requiring decompression surgery, a tumor located in the basal ganglia, 
thalamus, or brainstem, a patient treated for severe infection or recovering from major surgery, a 
history of IL-2 intolerance, and a history of ganciclovir and/or MRI contrast allergy or 
intolerance. Authors were not blinded to the results and no randomization was performed. 
 
Patient recruitment 
Seven patients (4 men, 3 women; mean age ± SD, 57 ± 8 years old) were prospectively enrolled 
from April 2006 to October 2013, in two separate clinical trials to evaluate the safety and 
feasibility of intratumoral immunotherapy with CTLs (Table 1). Patients 1 and 2 were treated 
with autologous CTLs (NCT00730613) (17), whereas Patients 3-7 received allogeneic CTLs 
(NCT01082926). Patients included in this study were diagnosed with recurrent glioblastoma 
overexpressing the IL-13Rα2 receptor, thus allowing the recognition of malignant glioma cells 
by the genetically modified CTLs (17, 19, 48). It has previously been shown that patient 
prognosis and survival are inversely proportional to the abundance of tumor-associated IL-
13Rα2 (25). Nevertheless, the presence of these specific targets helped to define patients who 
would likely benefit and respond to immunotherapy. No patient received additional radiotherapy 
 20 
or chemotherapy throughout this study. All patients were initially treated and followed up at the 
City of Hope, Duarte, California, USA. The Institutional Review Board and the local ethics 
committee approved all study protocols, and informed consent was obtained from each patient. 
 
CTL engineering 
The T-cell manufacturing process has been described previously in detail (17). For Patients 1-2: 
T-cells were expanded from clones that had been selected from genetically modified T-cells 
isolated from the patient’s peripheral blood mononuclear cells (PBMC). A plasmid DNA 
construct encoding the IL-13 zetakine CAR and the wild-type HSV1-tk genes under the 
transcriptional control of a modified human Elongation Factor-1 (EF-1) promoter and the 
cytomegalovirus (CMV) immediate/early promoter, was transfected into the isolated cells using 
electroporation in a cell production facility at the City of Hope, Duarte, (California, USA). 
Hygromycin resistant CTLs were cloned in limiting dilution, then expanded using the rapid 
expansion method (REM) method to numbers in excess of 109 and subsequently cryopreserved 
(17).  Following the diagnosis of tumor relapse the cryopreserved cells were thawed, REM 
expanded and formulated for intracranial infusion in 2 mL of preservative-free normal saline 
(PFNS). For Patients 3-7: The GRm13Z40-2 CTL line was derived from a healthy volunteer 
donor apheresis unit. The GRm13Z40-2 CTL line is an ex vivo expanded allogeneic genetically 
modified oligoclonal CD8+ cytotoxic T lymphocyte line that expresses the IL-13 zetakine CAR 
and contains a biallelic deletion in the glucocorticoid receptor (GR) to confer steroid resistance. 
PBMC were subjected to electroporation to introduce plasmid IL-13 zetakine CAR DNA, 
followed by activation with monoclonal antibody Muromonab CD3 (30 ng/mL; trade 
name Orthoclone OKT3, marketed by Janssen-Cilag), ex vivo REM expansion (17), and 
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selection in the presence of cytotoxic concentrations of hygromycin (0.2 mg/mL). Hygromycin-
selected IL-13 zetakine CTLs were then subjected to transfection using the chimeric Ad5/35 
adenovirus encoding a zinc finger nuclease (ZFN) pair that targets the human GR, which led to 
permanent disruption of the reading frame. Adenovirus transfected IL-13 zetakine CTLs were 
subjected to selection in dexamethasone. Surviving T cells underwent large-scale REM 
expansion followed by cryopreservation to generate an allogeneic IL-13 zetakine CTL bank. 
Following the diagnosis of recurrent GBM the cryopreserved cells were thawed and formulated 
for intracranial infusion in 2 mL of preservative-free normal saline (PFNS). 
 
Infusion methods 
Patients 1-2 underwent craniotomy for tumor resection and placement of Rickham reservoir and 
catheter for CTL injection, as previously detailed (17). These patients were treated with a series 
of twelve infusions of autologous CTLs (each over 10 minutes) on days 1, 3, and 5 over a period 
of 5 weeks, with a break on week 3. If the initial dose of 1 × 107 CTLs was tolerated, subsequent 
infusions were increased to 5 × 107 and then 1 × 108 autologous CTLs per injection. Patients 3-7 
had unresectable recurrent glioblastoma. These patients underwent stereotactic tumor biopsy and 
insertion of Rickham reservoir/catheter for intratumoral CTL infusion. These patients were 
treated with a series of four infusions of 1 × 108 allogeneic CTLs along with escalating doses of 
recombinant human IL-2 to prolong the survival of CTLs (49). Allogeneic CTLs were infused on 
days 1 and 3 for two consecutive weeks; IL-2 was infused on days 2, 3, 4, and 5 of the first week 
(2500 IU/day) and on days 1, 2, 3, 4, and 5 of the second week (5000 IU/day) (table S3). In 
Patient 3, CTLs and IL-2 were administered directly into the tumor cavity by convection-
enhanced delivery, which is a drug delivery strategy designed to circumvent the central nervous 
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system defense system and improve drug distribution (50). It allows for delivery of high 
concentrations of therapeutic agents directly into brain tumors and surrounding parenchyma with 
minimal systemic toxicity. Because of cell clumping associated with slow infusion, CTL delivery 
technique was switched to a “manual push” technique over 10 minutes in Patients 4-7.  
 
 
Clinical assessment 
Before each [18F]FHBG scan, we obtained a physical exam, a 12-lead electrocardiogram (ECG), 
vital signs (blood pressure, heart rate, respiratory rate, body temperature, and blood 
oxygenation), blood sampling (for complete blood chemistries, complete metabolic panel, 
international normalized ratio, and activated partial thromboplastin time), and urine (for urine 
analysis and pregnancy test, if needed). These values were used as a baseline. The patients’ 
routine medications and medical history were also recorded. Vital signs were taken at 5, 10, 15, 
60, and 120 minutes after [18F]FHBG injection. ECGs were monitored every 15 minutes up to 
120 minutes after the tracer injection and were analyzed for PQ/QRS and QT changes. 
 
After the PET scan was completed, another set of vital signs and ECG were collected. Within 24 
hours of the scan, the participants returned to the clinic, and vital signs and ECG were again 
collected, as well as blood and urine samples. Seven days later, a similar assessment was 
performed in addition to a neuropsychological test (mini mental state examination) that was also 
performed at baseline. Any adverse events noted by the members of the research team or the 
participants during the whole procedure were recorded for up to a week during follow-up. 
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Imaging studies 
9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine, or [18F]FHBG, was synthesized as previously 
described (22). The mean [18F]FHBG activity injected was 259 ± 7 MBq (7.0 ± 0.2 mCi), with 
no significant differences between pre- and post-CTL infusion PET scans (P > 0.05). The 
maximum amount of unlabeled product was less than 2 µg, and the specific activity was greater 
than 37Gbq/µmol (22). 
 
The tracer was administered as a bolus injection over less than 5 seconds via a hand or an arm 
vein. Approximately two hours after intravenous injection of [18F]FHBG, PET images were 
obtained from the skull vertex to mid-thighs. Scans for patients 1-2 were performed with a 
standalone PET scanner (Siemens ECAT EXACT™ HR+ PET scanner; CTI PET Systems, Inc.). 
[18F]FHBG PET scans, at 7 minutes per bed position, were performed for both Patients 1-2, but 
no baseline scan was done for Patient 1.(16). In addition, delayed brain PET images were 
obtained for Patient 1. After the emission scan, the patient underwent a transmission scan for 3 
minutes per bed position, using 3 rotating 68Ge rod sources. PET images were reconstructed with 
OSEM algorithm with attenuation correction on a 128 × 128 matrix size. The images for patients 
3-5 images were obtained with a PET/CT scanner (Siemens Biograph TruePoint 64-slice). A 
topogram scan (120 kVp, 35 mAs) was acquired, followed by a low-dose non-contrast CT 
(helical mode, rotation 0.5 sec, slice thickness 5.0 mm, 120 kVp, 100 mA) for attenuation 
correction and anatomic localization. PET images were obtained in 3D mode for 7 minutes per 
bed position, using an iterative reconstruction algorithm (2 iterations and 24 subsets) on a 168 × 
168 matrix size and a Gaussian filter cut-off of 5.0 mm. Images for Patients 6 and 7 were 
obtained on another PET/CT scanner (Siemens Biograph mCT 64-slice). All image protocols 
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were similar to those on the Biograph TruePoint, except for the matrix size, which was larger at 
200  ×  200. All PET images were decay corrected to the time of injection. Each patient was 
asked to void their bladder before each scan to reduce their total radiation exposure. All 
[18F]FHBG PET images were obtained at the University of California, Los Angeles, California, 
USA. All PET scanners were fully calibrated and tested for quantitative accuracy; these 
procedures were performed according to the manufacturer’s recommendations. 
 
In addition, brain [18F]FDG and MRI were performed before and after CTL infusions, using 
standard oncological protocols. These images were obtained at City of Hope, Duarte California, 
USA, and were scheduled within a few days of the [18F]FHBG imaging. 
 
Image analysis 
All data analyses were performed at Stanford University (California, USA), University College 
London (London, UK), and Hôpital de la Cité-de-la-Santé de Laval (Québec, Canada). 
[18F]FHBG images were co-registered to MRI images on MIM Encore v6.4, MIM Software and 
on Siemens Inveon v4.2, Research Workplace. Automatic image registration was applied 
initially, and manual positioning was performed as necessary. [18F]FHBG images were analyzed 
in all axial planes and with different thresholds to detect subtle abnormal uptake. Standardized 
uptake values (SUVs) were measured in different areas using a three-dimensional 50 mm 
diameter spherical volume of interest for healthy tissue. Values were obtained for the left 
ventricle of the heart (referred to as blood pool); the left and right lung parenchyma; the right 
hepatic dome (referred to as liver); the left and right quadriceps musculature (referred to as 
thigh); the bone marrow; the left and right frontal lobes, parietal lobes, temporal lobes, occipital 
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lobes, and the cerebellum (table S2). Activity within all brain areas except the site of surgical 
resection or tumor recurrence, was averaged to represent the background brain uptake. An 
irregular three-dimensional volume of interest was drawn over the abnormal uptake area in the 
brain (tumor recurrence and/or CTL foci): we used the native volume growth algorithm from 
MIM Encore 6.4, MIM Software, and we applied different thresholds for delineation. A 10% 
threshold of SUVmax was initially drawn, and 10% increments were subsequently applied until 
90% of SUVmax was obtained. MRI and [
18F]FHBG PET images were always compared side-by-
side to help in visual adjustment of boundaries. In addition, MRI and [18F]FHBG PET images 
were fused together to optimally visualize the uptake area. To do this, rigid-body registration 
with rotations was initially applied, followed by deformable registration. In most cases, the 
delineation on [18F]FHBG PET images followed the enhancing boundaries visualized on T1 post-
gadolinium sequence on MRI images. For treatment response, we always considered the 
background activity as part of baseline normal brain uptake. Therefore, we subtracted 
background activity from the activity measured in each volume of interest. 
 
Different strategies were used for evaluating therapy response: we used SUVmax, SUVmean, three-
dimensional volumes encompassing the tumor, individual voxel histogram analysis, and a 
parameter which takes into consideration the [18F]FHBG concentration and the volume of 
interest. This parameter, referred to as total activity, corresponds to the SUVmean multiplied by 
the volume of interest. To calculate the percentage of signal change between two scans, we used 
a formula that accounted for background activity in the brain:  
(𝑝𝑜𝑠𝑡 𝐶𝑇𝐿 𝑆𝑈𝑉 𝑙𝑒𝑠𝑖𝑜𝑛 − 𝑆𝑈𝑉 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) − (𝑝𝑟𝑒 𝐶𝑇𝐿 𝑆𝑈𝑉 𝑙𝑒𝑠𝑖𝑜𝑛 − 𝑆𝑈𝑉 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
𝑝𝑟𝑒 𝐶𝑇𝐿 𝑆𝑈𝑉 𝑙𝑒𝑠𝑖𝑜𝑛 − 𝑆𝑈𝑉 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 × 100 
Movie rendering was performed with Amira v5.2.2, Visage Imaging Inc. 
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Assessment of FHBG toxicity to transduced CTLs 
Patient-derived CTLs: GRm13Z40 (HD040-IL13z-ZFN) – Control cell ID# cJ05105 and WCB-
031-4C11-01 (UPN-031-IL13-zeta_DIIHyTK-pMG (pj00429#7)Cl.4C11) Cell ID# cj02331 
were obtained from the T cell therapeutics lab at City of Hope Hospital, Duarte, CA as frozen 
vials. The CTLs were recovered in RPMI medium with L-glutamine and Hepes. Human IL-2 (50 
units/mL) was added as a supplement. 15,000 cells for each cell type were plated in a 96 well 
tissue culture dish in RPMI medium. For the cells that needed to be exposed to the tracer, 7.4 
kBq of FHBG was added to each well. 1 h after exposure to tracer, cells were washed with PBS 
twice and either lysed for counting accumulated radioactivity or plated in medium for an 
additional 24 h and 48 h. Viability assessment was performed using the Presto Blue assay as per 
the manufacturer’s instructions (Thermofisher). Presto Blue uses the reducing environment of 
living cells to quantify viability. In brief, the desired volume of Presto Blue was added to the 
cells to a final concentration of 10%. The accumulated fluorescence was quantified using a 
microplate reader (excitation 540 nm, emission 600 nm), 30 min and 1 h after the addition of 
Presto Blue.  
 
Statistical analysis 
Statistical analysis was performed in Microsoft Excel 2010 v14.0.6 and GraphPad Prism 
Software v.5.0. Values were expressed as mean ± standard deviation (SD). To compare uptake in 
healthy organs before and after CTL infusions, and when comparing the effect of [18F]FHBG 
incubation on CTL proliferation rate, the Student paired t-test was used. For comparison of 
[18F]FHBG total activity measurement in lesions before and after CTL infusions for all patients, 
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a paired Wilcoxon test was used. Probability values less than 0.05 were considered as 
statistically significant. 
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Movie S1. Movie of tumor-associated [18F]FHBG activity in the same patient before and after 
CTL administration.  
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Table 1. Imaging and demographic data for all seven patients enrolled in this study.  
Patient # 1 2 3 4 5 6 7 
Gender M F F M F M M 
Age (years) 57 41 61 62 53 66 60 
CTL type autologous autologous allogeneic allogeneic allogeneic allogeneic allogeneic 
Histology Glioma Glioma Glioma Glioma Glioma Glioma Glioma 
IL13Rα2 
expression 
N/A N/A 2-3+ / 80% 2-3+ / 80% 2-3+ / 70% 2+ / 60% 2+ / 90% 
Site of 
primary 
tumor 
right 
parietal 
right 
parieto-
occipital 
splenium of 
corpus 
callosum 
and left 
parietal 
right 
occipital 
left 
temporal 
right fronto-
parietal 
left frontal 
Site of 
recurrence 
right 
occipital 
right 
parieto-
occipital 
splenium of 
corpus 
callosum 
and left 
parietal 
genu of 
corpus 
collosum 
and 
bifrontal  
left 
temporal 
right fronto-
parietal 
left parietal 
MRI pre-
CTL 
08/03/2006 15/01/2009 23/03/2011 15/02/2012 09/05/2012 12/09/2012 06/03/2013 
MRI post-
CTL 
18/04/2006 25/02/2009 15/05/2011 12/03/2012 05/06/2012 08/10/2012 26/03/2013 
[18F]FDG 
pre-CTL 
09/03/2006 14/01/2009 23/03/2011 15/02/2012 10/05/2012 14/09/2012 08/03/2013 
[18F]FDG 
post-CTL 
N/A N/A 16/05/2011 17/03/2012 06/06/2012 08/10/2012 27/03/2013 
[18F]FHBG 
pre-CTL 
N/A 05/01/2009 21/04/2011 17/02/2012 11/05/2012 13/09/2012 07/03/2013 
[18F]FHBG 
post-CTL 
17/04/2006 23/02/2009 09/05/2011 06/03/2012 01/06/2012 04/10/2012 28/03/2013 
Lesion 
total 
activity 
pre-CTL 
- 10.1 3.5 2.9 23.1 4.1 1.8 
Lesion 
total 
activity 
post-CTL 
#1, 4.9; #2, 0.8  20.3 8.4 6.3 28.1 8.4 6.8 
Non-
injected 
foci total 
activity 
pre-CTL 
- - - 2.4 - - 1.6 
Non-
injected 
foci total 
activity 
post-CTL 
- - - 3.2 - - 2.7 
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Figure legends 
 
Fig. 1. The herpes simplex virus type-1 thymidine kinase gene (HSV1-tk) complex and 
monitoring by [18F]FHBG. The herpes simplex virus type-1 thymidine kinase gene (HSV1-tk) 
complex is a genetically modified structure that was transfected into either autologous or 
allogeneic CTLs. This complex expresses a fusion protein consisting of a selective gene 
(hygromycin resistance locus) for adequate in vitro expansion of the CTL line; a PET reporter 
gene and safety gene, HSV1-tk; a glucocorticoid receptor (GR) resistance locus for improving 
CTL survival despite the high doses of steroids routinely given to high-grade glioma patients; 
and a IL-13 zetakine domain which is a chimeric receptor that enables glioma cell recognition by 
CTLs. CTL transfection was performed by electroporation. Inside the transfected cells, HSV1-tk 
is transcribed and translated to produce the HSV1-TK enzyme. [18F]FHBG is a labeled analog of 
penciclovir and substrate for HSV1-TK. In the presence of HSV1-TK, the radiolabeled probe is 
phosphorylated and trapped within the cell. The magnitude of [18F]FHBG signal reflects the 
activity of HSV1-TK enzyme and thus HSV1-tk gene expression. Abbreviation: pmRNA, pre-
messenger RNA.  
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Fig. 2. Schematic demonstrating the workup and monitoring of CTL infusion after an 
initial treatment for high-grade glioma. After enrollment in this study and upon tumor 
recurrence, an intracerebral Rickham catheter was installed for repetitive infusions of CTLs. 
Each patient underwent [18F]FHBG PET and MRI before and after CTL infusions. In addition, 
IL-2 was administered at regular intervals to further increase the survival and enhance the 
potency of the administered CTLs. CTL distribution was imaged by measuring changes in 
tumoral [18F]FHBG accumulation before and after infusions of cells. 
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Fig. 3. Tumor-associated CTL imaging with [18F]FHBG. [18F]FHBG PET imaging was 
performed in a 66 year-old male (Patient 6) with a recurrent right frontoparietal glioblastoma 
before (A) and one week after (B) CTL infusions. Allogeneic CTLs and IL-2 were injected 
intratumorally (red arrows) as described in Materials and Methods. Tumor recurrence was 
monitored by T1-weighted (T1W) MRI (top panels). [
18F]FHBG PET images were fused with 
MRI images (bottom panels), and 3D volumes of interest were drawn using a 50% [18F]FHBG 
SUVmax threshold, outlined in yellow. (C) Voxel-wise analysis of [
18F]FHBG SUV in pre- and 
post-CTL infusion scans. 
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Fig. 4. [18F]FHBG PET imaging in recurrent disease and at untreated tumor sites. 
[18F]FHBG PET imaging was performed in a 60 year-old male (Patient 7) with multifocal left 
hemispheric glioma. CTLs were injected into the medial left frontal lobe tumor (yellow arrows).  
(A) Tumor size was monitored by T1-weighted (T1W) contrast-enhanced MRI (top left panels). 
[18F]FHBG PET images were fused with MRI images (bottom left panels), and 3D volumes of 
interest were drawn using a 50% [18F]FHBG SUVmax threshold, outlined in red. (B) MRI and 
[18F]FHBG PET-MR images one week after CTL infusions. (C) Voxel-wise analysis of 
[18F]FHBG total radioactivity in pre- and post-CTL infusion scans. [18F]FHBG activity was 
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additionally assessed in a non-injected tumor focus (red arrows) before (D) and after (E) CTL 
infusions, with voxel-wise analysis of this lesion performed for comparison (F). 
 
 
Fig. 5. Changes in [18F]FHBG total activity in patients after CTL infusions. The total 
activity (SUVmean × uptake volume) was measured for each patient on pre- and post-CTL 
[18F]FHBG scans, with the VOI obtained after a 50% SUVmax threshold. Clinically-confirmed 
sites of tumor recurrence that received CTL infusions are indicated in blue. Non-injected tumor 
foci in patients with multifocal disease are indicated in gray. In Patient 1, for whom no pre-CTL 
scan was available, the total activity values for the two tumor foci are shown in red. For 
reference, patient numbers are indicated next to the post-CTL [18F]FHBG values. The increase in 
[18F]FHBG signal after CTL infusion was statistically significant (P = 0.014; paired Wilcoxon 
test). 
